Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

New COX-2 inhibitor series reported by Searle

Aug. 22, 1997

Celgene receives patent for SelCID

Aug. 21, 1997

Boston Life Sciences completes phase III trial of Therafectin

Aug. 20, 1997

Salagen approved for Sjogren's syndrome in Canada

Aug. 20, 1997

New treatment for osteoarthritis approved for marketing in U.S.

Aug. 18, 1997

Antiinflammatory drugs in early development at Searle

Aug. 13, 1997

MMP/TNF-alpha inhibitors from Novartis

Aug. 12, 1997

Amarillo Biosciences completes enrollment for phase II study on Sjogren's syndrome

Aug. 12, 1997

Cephalon reports cysteine/serine protease inhibitors with broad therapeutic potential

Aug. 11, 1997

Antiarthritic activity of British Biotech MMP/TNF-alpha inhibitors

Aug. 8, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...